top of page
Revive Innovation+
Country/Region:
United Kingdom
Year Joined:
2022 (Batch 8)
Revive's first application is an adrenaline auto-injector (AAI) for the emergency treatment of anaphylaxis. Many patients at risk of severe allergies do not carry an AAI because existing AAIs are large, bulky and draw unwanted attention. Revive's solution is a compact and patient-friendly pre-loaded injector that effectively delivers life-saving adrenaline, ensuring timely and discreet treatment for those in need.
bottom of page